Noninfectious uveitis: Management with biologic agents
Indian Journal of Ophthalmology · 2026-06 · 74 (6) · 837-844
DOI: 10.4103/ijo.ijo_3239_25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 12.03.2026. Verfasst von S R Rathinam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Uveitis Service, Aravind Eye Hospital and PG Institute of Ophthalmology, Madurai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Uveitis, Biological Factors, Disease Management, Biological Products. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Uveitis is an inflammatory condition involving the iris, ciliary body, and choroid, and it represents a significant cause of vision loss in both children and adults. The primary goals of uveitis management are to control inflammation, prevent recurrences, and minimize structural damage and subsequent visual impairment. Currently, corticosteroids remain the mainstay of therapy for noninfectious uveitis. In patients with sight-threatening disease, immunosuppressive or steroid-sparing agents are commonly employed. However, for individuals who are intolerant of or refractory to corticosteroids and conventional immunosuppressive therapies, biologic agents have emerged as effective alternative treatments. Among these, anti-tumor necrosis factor alpha (TNF-α) agents have demonstrated efficacy in both uveitis and systemic autoimmune disorders. Adalimumab, an anti-TNF-α agent, was the first biologic approved by the U.S. Food and Drug Administration for the treatment of noninfectious uveitis. Prior to initiating biologic therapy, potential safety concerns, including the risk of infections and demyelinating diseases, must be carefully evaluated. Other biologic agents, such as interferons, interleukin inhibitors, and Janus kinase inhibitors, are emerging as promising therapeutic options for noninfectious uveitis. Further studies are required to better establish the long-term safety and efficacy of biologic therapies. This review highlights the role and effectiveness of biologic agents in the management of noninfectious uveitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Uveitis Service, Aravind Eye Hospital and PG Institute of Ophthalmology, Madurai, Tamil Nadu, India.
Zitieren
APA
Rathinam, S. R., & Anjana, S. (2026). Noninfectious uveitis: Management with biologic agents. Indian Journal of Ophthalmology, 74(6), 837-844. https://doi.org/10.4103/ijo.ijo_3239_25
Vancouver
Rathinam SR, Anjana S. Noninfectious uveitis: Management with biologic agents. Indian Journal of Ophthalmology. 2026;74(6):837-844. doi:10.4103/ijo.ijo_3239_25
BibTeX
@article{Rathinam2026,
author = {Rathinam, S R and Anjana, Somanath},
title = {Noninfectious uveitis: Management with biologic agents},
journal = {Indian Journal of Ophthalmology},
year = {2026},
volume = {74},
number = {6},
pages = {837--844},
doi = {10.4103/ijo.ijo_3239_25}
}
EUVIMED